4 results on '"Seth, Ashok"'
Search Results
2. One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience.
- Author
-
Elkoumy, Ahmed, Jose, John, Terkelsen, Christian Juhl, Nissen, Henrik, Gunasekaran, Sengottuvelu, Abdelshafy, Mahmoud, Seth, Ashok, Elzomor, Hesham, Kumar, Sreenivas, Bedogni, Francesco, Ielasi, Alfonso, Arsang-Jang, Shahram, Dora, Santosh Kumar, Chandra, Sharad, Parikh, Keyur, Unic, Daniel, Baumbach, Andreas, Serruys, Patrick, and Soliman, Osama
- Subjects
AORTIC stenosis ,MITRAL valve ,HEART valve prosthesis implantation ,CARDIAC pacemakers ,AORTIC valve transplantation ,AORTIC valve ,HEART valves - Abstract
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% of candidates for aortic valve replacement (AVR). Despite increasingly utilised transcatheter aortic valve implantation (TAVI) in aortic stenosis (AS) patients, its use among patients with severe bicuspid AS is limited as BAV is a heterogeneous disease associated with multiple and complex anatomical challenges. Aim: To investigate the one-year outcomes of TAVI using the balloon-expandable Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd., Vapi, India) in patients with severe bicuspid AS. Methods and results: We collected data from consecutive patients with bicuspid AS who underwent TAVI with the Myval THV and had at least one-year follow-up. Baseline characteristics, procedural, and 30-day echocardiographic and clinical outcomes were collected. Sixty-two patients were included in the study. The median age was 72 [66.3, 77.0] years, 45 (72.6%) were males, and the mean STS PROM score was 3.2 ± 2.2%. All TAVI procedures were performed via the transfemoral route. The median follow-up duration was 13.5 [12.2, 18.3] months; all-cause mortality was reported in 7 (11.3%) patients and cardiovascular hospitalisation in 6 (10.6%) patients. All-stroke was reported in 2 (3.2%), permanent pacemaker implantation 5 (8.3%), and myocardial infarction 1 (1.6%) patients. The echocardiographic assessment revealed a mean pressure gradient of 10 [8, 16.5] mmHg, effective orifice area 1.7 [1.4, 1.9] cm
2 , moderate AR in 1 (2%), mild AR in 14 (27%), and none/trace AR in 37 (71%). In total, 1 patient was diagnosed with valve thrombosis (2.1%), Stage II (moderate) haemodynamic deterioration was seen in 3 (6.4%), and stage III (severe) haemodynamic deterioration in 1 (2.1%) patient. Conclusions: TAVI with the Myval THV in selected BAV anatomy is associated with favourable one-year hemodynamic and clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosis—A Multicenter Real-World Experience.
- Author
-
Elkoumy, Ahmed, Jose, John, Terkelsen, Christian J., Nissen, Henrik, Gunasekaran, Sengottuvelu, Abdelshafy, Mahmoud, Seth, Ashok, Elzomor, Hesham, Kumar, Sreenivas, Bedogni, Francesco, Ielasi, Alfonso, Dora, Santosh K., Chandra, Sharad, Parikh, Keyur, Unic, Daniel, Wijns, William, Baumbach, Andreas, Mylotte, Darren, Serruys, Patrick, and Soliman, Osama
- Subjects
HEART valve prosthesis implantation ,AORTIC stenosis ,MITRAL valve ,AORTIC valve insufficiency ,AORTIC valve ,HEART valves - Abstract
Bicuspid aortic valve (BAV) is the most common valvular congenital anomaly and is apparent in nearly 50% of candidates for AV replacement. While transcatheter aortic valve implantation (TAVI) is a recommended treatment for patients with symptomatic severe aortic stenosis (AS) at all surgical risk levels, experience with TAVI in severe bicuspid AS is limited. TAVI in BAV is still a challenge due to its association with multiple and complex anatomical considerations. A retrospective study has been conducted to investigate TAVI's procedural and 30-day outcomes using the Myval transcatheter heart valve (THV) (Meril Life Sciences Pvt. Ltd. Vapi, Gujarat, India) in patients with severe bicuspid AS. Data were collected on 68 patients with severe bicuspid AS who underwent TAVI with the Myval THV. Baseline characteristics, procedural, 30-day echocardiographic and clinical outcomes were collected. The mean age and STS PROM score were 72.6 ± 9.4 and 3.54 ± 2.1. Procedures were performed via the transfemoral route in 98.5%. Major vascular complications (1.5%) and life-threatening bleeding (1.5%) occurred infrequently. No patient had coronary obstruction, second valve implantation or conversion to surgery. On 30-day echocardiography, the mean transvalvular gradient and effective orifice area were 9.8 ± 4.5 mmHg and 1.8 ± 0.4 cm
2 , respectively. None/trace aortic regurgitation occurred in 76.5%, mild AR in 20.5% and moderate AR in 3%. The permanent pacemaker implantation rate was 8.5% and 30-day all-cause death occurred in 3.0% of cases. TAVI with the Myval THV in selected BAV anatomy is associated with favorable short-term hemodynamic and clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication.
- Author
-
Elkoumy, Ahmed, Jose, John, Gunasekaran, Sengottuvelu, Kumar, Asish, Srinivas, B.C., Manjunath, C.N., Ravindranath, K.S., Parekh, Maulik, Chandra, Praveen, Kapoor, Rajneesh, Abdelshafy, Mahmoud, Seth, Ashok, Agrawal, Praveer, Mathur, Atul, Rao, Ravindra Singh, Elzomor, Hesham, Sadanada, K.S., Kumar, Vijay, Arsang-Jang, Shahram, and Mehrotra, Sanjay
- Subjects
- *
AORTIC valve insufficiency , *HEART valve prosthesis implantation , *ANGIOGRAPHY , *AORTIC valve , *HEART valves , *TRICUSPID valve - Abstract
The balloon expandable Myval transcatheter heart valve (THV) showed encouraging results regarding residual aortic regurgitation (AR) from multiple observational studies. The newly designed Myval Octacor has been introduced recently, aiming for a reduction in AR and improved performance. The focus of this study is to report the incidence of AR using the validated quantitative Videodensitometry angiography technology (qLVOT-AR%) in the first in human use of the Myval Octacor THV system. We report on the first in human use of the Myval Octacor THV system in 125 patients in 18 Indian centres. Independent retrospective analysis of the final aortograms following implantation of the Myval Octacor was performed using the CAAS-A-Valve software. AR is reported as a regurgitation fraction. The previously validated cutoff values have been used to identify ≥moderate AR (RF% >17%), mild (6% < RF% ≤17%), and none or trace AR (RF% ≤ 6%). Final aortogram was analysable for 103 patients (84.4%) among the 122 available aortograms. 64 (62%) patients, had tricuspid aortic valve (TAV), 38 (37%) with bicuspid AV (BAV), and one with unicuspid AV. The median absolute RF% was 2% [1, 6], moderate or more AR incidence was 1.9%, mild AR in 20.4%, and none or trace AR in 77.7%. The two cases with RF% >17% were in the BAV group. The initial results of Myval Octacor using quantitative angiography-derived regurgitation fraction demonstrated a favourable outcome regarding residual AR, possibly due to improved device design. Results must be confirmed in a larger randomised study, including other imaging modalities. • The new BE Myval Octacor THV shows changes in cell design to minimise over-shortening of the device. • The improved internal and external skirt design shows improvement in the incidence of residual AR. • In comparison to the First Myval iteration, Myval Octacor shows a significant reduction of moderate or more AR. • A reduction of mild AR with a shift to none/trace AR was observed when AR was assessed using quantitative technology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.